ClinicalTrials.gg
RecruitingNCT07506395GPATUpdated May 22, 2026

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

A Phase 1 interventional study of Psilocybin in PTSD, sponsored by University of New Mexico. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University of New Mexico · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Planned enrollment
10th of 20
36 · median 33
Started
2026
with 6 others
Phase 1
6 of 20
5 open now
Primary completion
2027-05
later than 7 of 15 live
Registered
16th of 20
by date
Lead sponsor
2 of 20
University of New Mexico

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 10th largest by planned enrollment, is one of 7 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 7 of the 15 other live ones, and was the 16th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.

Read the detailed description

This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.

These will be assessed by the following outcome measures:

  • Proportion of participants completing the study protocol
  • Incidence of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • Mean change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and PTSD checklist for DSM-5 (PCL-5). The CAPS-5 and PCL-5 are based on the DSM-5 not the DSM-5-TR.
03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General:

-T+H years of age and \<89 years of age

Identify as a member of one of the cohorts to be studied:

  • Veteran or first responder
  • Female survivor of sexual violence
  • Indigenous person
  • Not pregnant, planning to become pregnant, or breastfeeding; if able to become pregnant, willing to use reliable form of for the duration of the study
  • If needed, ability and willingness to taper and discontinue medications that may interfere with the action of psilocybin
  • Ability to read, speak, and understand English
  • Ability and willingness to consent to the terms of the study, including attending all trial visits (most of which will occur in a group setting), preparation and
  • follow-up sessions, and completing all trial evaluations
  • Ability and willingness to swallow capsules

PTSD severity:

  • Meet criteria for PTSD, as defined in the
  • At screening, symptoms of moderate to severe PTSD (PCL-5 score of 34 or greater) present for at least six months

Exclusion criteria

Exclusion Criteria:

  • Inability to achieve five days of abstinence from alcohol, non-prescribed opioids, methamphetamines, cocaine, benzodiazepines, or other illicit substances
  • Inability or unwillingness to remain abstinent from cannabis use for 24 hours prior to psilocybin dosing session and 12 hours after receiving the dose of psilocybin
  • Risk for acute withdrawal from any substance that would cause safety concern on the day of dosing
  • Any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, (ECG), and clinical laboratory tests: Pregnancy/breastfeeding

Cardiovascular conditions:

  • Uncontrolled hypertension, defined as >140/90 mm Hg at screening or baseline or >145/95 mm Hg on presentation for dosing day assessed on three consecutive blood pressure measurements
  • History of myocardial infarction, cardiac ischemia, congestive heart failure, clinically relevant valvular heart disease, or pulmonary hypertension; any other significant history of cardiovascular condition, based on the clinical judgment of the Trial Physician, which would make a participant unsuitable for the trial
  • ECG: Clinically significant abnormality (e.g. atrial fibrillation based on judgement of trial physician including prolonged interval (QTc> 450 milliseconds (males) or >470 milliseconds (females)
  • Poorly controlled diabetes ( >8.0%; clinically significant hypoglycemia in the past 6 months)
  • Neurological conditions (e.g. epilepsy or other seizure disorder) or neurodegenerative disease (e.g., dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis.), or brain tumor that would impact participation in the trial Serious abnormalities of complete blood count or chemistry

    • Severe hepatic impairment
    • Severe renal impairment,
    • Unstable existing thyroid disorder
  • Any of the following psychiatric conditions:

    • Active suicidal ideation; history of hospitalization for suicide attempt within the 12 months prior to screening, affirmative responses to C-SSRS questions 4 or 5
    • Confirmed diagnosis of schizophrenia or other psychotic disorder, firstdegree relative with schizophrenia
    • Axis-II diagnosis
  • Use of psychedelics (e.g., psilocybin, mescaline, ayahuasca, DMT, LSD, MDMA, or ketamine) resulting in a discrete psychedelic experience in the past six months.

Using daily dose of psilocybin mushrooms at dose \<0.2 mg or LSD at \<20 mcg per day for \<30 days in a year ("microdosing") will not be an exclusion criterion.

However, participants must agree to no further use of psychedelics during this study starting at screening.

  • Returning to an unsafe environment and/or inadequate social support-Any other condition, physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial.-
  • Participation in experimental treatment for PTSD or any research studies within 30 days of screening assessment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    GPAT-PTSD

    Drug: Psilocybin

Interventions

  • Two group-format dosing sessions, scheduled 4 weeks apart, will be held at the ISUBI Center at UNM or a site outside of UNM with DEA approval for psilocybin storage

06

What researchers measure

Primary outcomes

  1. Rate of study completion-feasabiity measure

    Number of participants that completed the study.

    Time frame: 18 weeks after baseline

  2. Clinician-Administered PTSD Scale for DSM-5

    The Clinician-Administered PTSD Scale for DSM-5 is a 30-item structured interview that determines a PTSD diagnosis and severity by assessing the frequency and intensity of 20 DSM-5 symptoms. Each symptom is rated on a 0-4 scale (0=absent, 4=extreme), with a total severity score calculated by summing individual item scores. Total Range: 0-80 (sum of 20 items) total scores indicate severity, with higher ratings indicating worse PTSD symptoms.

    Time frame: baseline and 18 weeks

  3. Incidence of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    adverse event assessment as safety measure

    Time frame: 18 weeks after baseline

Secondary outcomes

  1. Beck Depression Inventory-II

    The Beck Depression Inventory-II is a 21-item, 4-point Likert scale (0-3) self-report questionnaire depression assessment with a minimum score of 0 and a maximum score of 63; higher scores indicate greater depression severity.

    Time frame: 12 weeks after second psilocybin administration

  2. Hamilton Anxiety Scale

    The Hamilton Anxiety Scale is a 14-item clinician-administered tool used to quantify the severity of anxiety symptoms. Each item is scored from 0 (not present) to 4 (very severe), with a total score range of a minimum score of 0 and a maximum score of 56. Higher scores indicate higher anxiety symptoms.

    Time frame: 12 weeks after second psilocybin administration

  3. Sheehan Disability Scale

    The Sheehan Disability Scale is a 3-item self-reported tool measuring functional impairment in work, social life, and family life, each rated from 0 (not at all) to 10 (extremely). Total scores range from a minimum score of 0 and a maximum score of 30; higher scores indicate greater impairment.

    Time frame: 12 weeks after second psilocybin administration

  4. World Health Organization 5-Wellbeing Index

    The World Health Organization 5-Wellbeing Index is a 5-item, self-reported questionnaire assessing subjective psychological well-being over the past two weeks. Respondents rate items from 0 ("at no time"), with total raw scores (0-25) multiplied by 4, to generate a final 0-100 score. A maximum score of 100 indicates the best well-being, while a minimum score of 0 indicates the worst.

    Time frame: 12 weeks after second psilocybin administration

07

Study locations

1 of 1 sites recruiting
  • Interdisciplinary Substance Use and Brain Injury (ISUBI)
    Albuquerque, New Mexico 87131, United States
    Recruiting
08

References and documents

Publications

  • Leeman L, Armstrong M, Menashi D, Nayo-Washington H, Marseille E, Herrera J, Romero C, Page-Reeves J. Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico. Front Public Health. 2026 Jun 17;14:1845943. doi: 10.3389/fpubh.2026.1845943. eCollection 2026. PubMed 42395285 ↗

Individual participant data

Plan to share: No — no plans to share IPD

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 47 non-industry phase 1 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 33 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 1, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07506395
Responsible party
Lawrence Leeman (Professor, University of New Mexico) — Principal investigator
First posted
Apr 1, 2026
Start date
May 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Victoria Culkin
Contact
vculkin@salud.unm.edu

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion